Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Mounjaro side effect explained as more than 220,000 Brits are expected to receive the drug over the next three years ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Diabetes drug Tirzepatide, which is shown to be more effective than Wegovy and Ozempic, is likely to be approved by the Food and Drug Administration for weight loss in 2023 and is expected to be ...

Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss. According to the Health Survey for England 2022, around 64% of adults are ...